Publication date: Available online 6 March 2018
Source:Critical Reviews in Oncology/Hematology
Author(s): Marzia Del Re, Stefania Crucitta, Giuliana Restante, Eleonora Rofi, Elena Arrigoni, Elisa Biasco, Andrea Sbrana, Erika Coppi, Luca Galli, Sergio Bracarda, Daniele Santini, Romano Danesi
Tumor heterogeneity strongly affects the molecular mechanisms driving resistance to hormonal therapies in castration-resistant prostate cancer. Since the current use of available treatments can be optimized on the basis of the molecular profile of tumor, the present review focuses on genetic biomarkers in prostate cancer and their application for a personalized treatment.
http://ift.tt/2FyMJLO
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,
Ετικέτες
Τετάρτη 7 Μαρτίου 2018
Pharmacogenetics of androgen signaling in prostate cancer: focus on castration resistance and predictive biomarkers of response to treatment
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου